{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:37:00Z","timestamp":1790627820057,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Bausch and Lomb, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.ophtha.2013.07.006","type":"journal-article","created":{"date-parts":[[2013,9,7]],"date-time":"2013-09-07T22:17:05Z","timestamp":1378592225000},"page":"25-33","source":"Crossref","is-referenced-by-count":31,"title":["Bromfenac Ophthalmic Solution 0.07% Dosed Once Daily for Cataract Surgery"],"prefix":"10.1016","volume":"121","clinical-trial-number":[{"clinical-trial-number":"nct01367249","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Thomas R.","family":"Walters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien F.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Peace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Gow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2013.07.006_bib1","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s11136-012-0270-z","article-title":"Measuring the impact of cataract surgery on generic and vision-specific quality of life","volume":"22","author":"Groessl","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ophtha.2013.07.006_bib2","first-page":"17","article-title":"Vision 2020: the cataract challenge","volume":"13","author":"Foster","year":"2000","journal-title":"Community Eye Health"},{"key":"10.1016\/j.ophtha.2013.07.006_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archopht.122.4.487","article-title":"Prevalence of cataract and pseudophakia\/aphakia among adults in the United States","volume":"122","author":"Eye Diseases Prevalence Research Group","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.07.006_bib4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/archopht.1991.01080070105046","article-title":"Prevalence of lens opacities in surgical and general populations","volume":"109","author":"Adamsons","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.07.006_bib5","first-page":"641","article-title":"Population-based study on prevalence and risk factors of age-related cataracts in Peitou, Taiwan","volume":"63","author":"Cheng","year":"2000","journal-title":"Zhonghua Yi Xue Za Zhi (Taipei)"},{"key":"10.1016\/j.ophtha.2013.07.006_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Eye Diseases Prevalence Research Group","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.07.006_bib7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0161-6420(99)00024-X","article-title":"Diet and cataract: the Blue Mountains Eye Study","volume":"107","author":"Cumming","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.07.006_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/archopht.116.2.219","article-title":"Incidence of age-related cataract: the Beaver Dam Eye Study","volume":"116","author":"Klein","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.07.006_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2003.05.010","article-title":"Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study","volume":"111","author":"Buch","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.07.006_bib10","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/S0161-6420(01)00823-5","article-title":"Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study","volume":"108","author":"Buch","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.07.006_bib11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1185\/030079905X50651","article-title":"Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care","volume":"21","author":"O'Brien","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ophtha.2013.07.006_bib12","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2165\/00003495-200767090-00004","article-title":"The role of NSAIDs in the management of postoperative ophthalmic inflammation","volume":"67","author":"Colin","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ophtha.2013.07.006_bib13","first-page":"382","article-title":"Time course of rabbit ocular inflammatory response and mediator release after intravitreal endotoxin","volume":"31","author":"Csukas","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.07.006_bib14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/bjo.80.5.480","article-title":"The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology","volume":"80","author":"Koay","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.07.006_bib15","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1096\/fj.03-0645rev","article-title":"Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic","volume":"18","author":"Warner","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.ophtha.2013.07.006_bib16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jcrs.2007.05.015","article-title":"In\u00a0vivo pharmacokinetics and in\u00a0vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac","volume":"33","author":"Walters","year":"2007","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.ophtha.2013.07.006_bib17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00055735-199808000-00007","article-title":"Topical nonsteroidal anti-inflammatory agents in ophthalmology","volume":"9","author":"Nichols","year":"1998","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.07.006_bib18","series-title":"Bromday [package insert]","year":"2011"},{"key":"10.1016\/j.ophtha.2013.07.006_bib19","series-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics","first-page":"141","article-title":"Muscarinic receptor agonists and antagonists","author":"Brown","year":"1996"},{"key":"10.1016\/j.ophtha.2013.07.006_bib20","first-page":"513","article-title":"The analgesic and antiinflammatory activity and pharmacologic properties of bromfenac","volume":"37","author":"Sancilio","year":"1987","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ophtha.2013.07.006_bib21","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1021\/jm00377a001","article-title":"Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues","volume":"27","author":"Walsh","year":"1984","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.ophtha.2013.07.006_bib22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/jop.2007.0082","article-title":"24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits","volume":"24","author":"Baklayan","year":"2008","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2013.07.006_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1208\/s12248-008-9024-9","article-title":"Topical ocular delivery of NSAIDs","volume":"10","author":"Ahuja","year":"2008","journal-title":"AAPS J"},{"key":"10.1016\/j.ophtha.2013.07.006_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/OPTH.S4806","article-title":"Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution","volume":"3","author":"Cho","year":"2009","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.07.006_bib25","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ophtha.2006.12.029","article-title":"Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation","volume":"114","author":"Donnenfeld","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.07.006_bib26","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ophtha.2011.04.035","article-title":"Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain","volume":"118","author":"Henderson","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.07.006_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00002508-200405000-00001","article-title":"Analgesics for acute pain: meeting the United States Food and Drug Administration's requirements for proof of efficacy","volume":"20","author":"Ridgway","year":"2004","journal-title":"Clin J Pain"},{"key":"10.1016\/j.ophtha.2013.07.006_bib28","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1185\/03007995.2011.597663","article-title":"Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain","volume":"27","author":"Silverstein","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ophtha.2013.07.006_bib29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/jop.2007.0132","article-title":"Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor","volume":"24","author":"Miyake","year":"2008","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2013.07.006_bib30","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.jcrs.2009.03.054","article-title":"Efficacy of ophthalmic nonsteroidal antiinflammatory drugs in suppressing anterior capsule contraction and secondary posterior capsule opacification","volume":"35","author":"Mukai","year":"2009","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.ophtha.2013.07.006_bib31","series-title":"Bronuck [package insert]","year":"2009"},{"key":"10.1016\/j.ophtha.2013.07.006_bib32","series-title":"Xibrom [package insert]","year":"2010"},{"key":"10.1016\/j.ophtha.2013.07.006_bib33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","article-title":"Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use","volume":"144","author":"Robin","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.07.006_bib34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/01.ico.0000177835.93130.d4","article-title":"Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug","volume":"25","author":"Asai","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2013.07.006_bib35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00002018-200225040-00002","article-title":"Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review","volume":"25","author":"Gaynes","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.ophtha.2013.07.006_bib36","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jcrs.2007.04.041","article-title":"Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use","volume":"33","author":"Isawi","year":"2007","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.ophtha.2013.07.006_bib37","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.jcrs.2007.06.043","article-title":"Nepafenac-associated corneal melt","volume":"33","author":"Wolf","year":"2007","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.ophtha.2013.07.006_bib38","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1517\/14656560903188425","article-title":"Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent","volume":"10","author":"Jones","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ophtha.2013.07.006_bib39","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/jop.2007.0040","article-title":"Bromfenac Ophthalmic Solution 0.09% Study Group. The systemic safety of bromfenac ophthalmic solution 0.09%","volume":"23","author":"Stewart","year":"2007","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2013.07.006_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.iio.0000212134.83513.11","article-title":"Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug","volume":"46","author":"Donnenfeld","year":"2006","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.ophtha.2013.07.006_bib41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1517\/17425255.4.4.453","article-title":"Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing","volume":"4","author":"Abelson","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ophtha.2013.07.006_bib42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.17925\/EOR.2011.05.01.20","article-title":"New look at ocular inflammation control\u2014powerful and fast-acting twice-daily bromfenac for a novel standard in the treatment of inflammation","volume":"5","author":"Cho","year":"2011","journal-title":"Eur Ophthalmic Rev"},{"key":"10.1016\/j.ophtha.2013.07.006_bib43","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1167\/iovs.07-0720","article-title":"A\u00a0rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride","volume":"49","author":"Xiong","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.07.006_bib44","unstructured":"Prolensa [package insert]. Tampa, FL: Bausch & Lomb Inc; Revised April 2013. Available at: http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=4e072537-f73c-4a96-a65f-e2805ce112d8. Accessed June 27,\u00a02013."}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642013005952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642013005952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T14:37:51Z","timestamp":1531233471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642013005952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0161642013005952"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2013.07.006","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}